World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
35766
World Ranking
13922
National Ranking
7066

Steven M. Devine publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Steven M. Devine sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 545 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Steven M. Devine D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Steven M. Devine sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Steven M. Devine is affiliated with The Ohio State University in the United States and has a significant research profile in the field of medicine, specifically focusing on hematology, transplantation, and oncology. Their work encompasses multiple subfields such as public health, environmental and occupational health, immunology, and transplantation, underpinning a comprehensive approach to hematopoietic and cancer research.

Their research primarily addresses key topics including hematopoietic stem cell transplantation, acute myeloid leukemia research, acute lymphoblastic leukemia research, renal transplantation outcomes and treatments, chronic myeloid leukemia treatments, immune cell function and interaction, and cancer genomics and diagnostics.

Steven M. Devine has published extensively in several well-known venues, reflecting their active engagement within the scientific community. Frequent publication venues include:

  • Transplantation and Cellular Therapy
  • Blood
  • Blood Advances
  • Biology of Blood and Marrow Transplantation
  • Journal of Clinical Oncology

Some recent papers authored or co-authored by Steven M. Devine are:

  • Current Use of and Trends in Hematopoietic Cell Transplantation in the United States, 2020, Biology of Blood and Marrow Transplantation
  • Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial, 2020, Blood
  • National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide, 2021, Journal of Clinical Oncology
  • Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3, 2024, Journal of Clinical Oncology
  • DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, 2023, JAMA

Their collaborations include frequent co-authorship with several other scientists. Notable co-authors include:

  • Bronwen E. Shaw
  • Stephen R. Spellman
  • Jeffery J. Auletta
  • Brent R. Logan
  • Heather E. Stefanski

Steven M. Devine's contribution to the literature is predominantly centered on hematopoietic stem cell transplantation and leukemia research, with a strong emphasis on transplantation outcomes, immune interactions, and genomic diagnostics. Their scholarly output, spanning multiple years, presents a detailed and evolving perspective on treatments and clinical trials related to blood and marrow transplantation.

Best Publications

  • Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

    Amelia Bartholomew;Cord Sturgeon;Mandy Siatskas;Karen Ferrer

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

    Hillard M. Lazarus;Omer N. Koc;Steven M. Devine;Peter Curtin

  • Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates

    Steven M Devine;Carrington Cobbs;Matt Jennings;Amelia Bartholomew

  • The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

    Don M. Benson;Courtney E. Bakan;Anjali Mishra;Craig C. Hofmeister

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

    Voravit Ratanatharathorn;Richard A. Nash;Donna Przepiorka;Steven M. Devine

  • Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

    Claudio G. Brunstein;Ephraim J. Fuchs;Shelly L. Carter;Chatchada Karanes

  • Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    Stefan O. Ciurea;Mei Jie Zhang;Andrea A. Bacigalupo;Asad Bashey

  • International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

    Andrew C. Harris;Andrew C. Harris;Rachel Young;Rachel Young;Steven Devine;William J. Hogan

  • The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

    Neal Flomenberg;Steven M. Devine;John F. DiPersio;Jane L. Liesveld

  • Current Use and Trends in Hematopoietic Cell Transplantation in the United States

    Anita D'Souza;Anita D'Souza;Stephanie Lee;Stephanie Lee;Xiaochun Zhu;Marcelo Pasquini;Marcelo Pasquini

  • Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

    Steven M. Devine;Amelia M. Bartholomew;Nadim Mahmud;Mary Nelson

  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Bart L. Scott;Marcelo C. Pasquini;Brent R. Logan;Juan Wu

  • Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

    Steven M. Devine;Neal Flomenberg;David H. Vesole;Jane Liesveld

  • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

    William Blum;Ramiro Garzon;Rebecca B. Klisovic;Sebastian Schwind

  • Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

    Philippe Armand;Arnon Nagler;Edie A. Weller;Steven M. Devine

  • CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianhong Chu;Youcai Deng;Don M. Benson;Shun He

  • Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

    Sergio Giralt;Luciano Costa;Jeffrey Schriber;John DiPersio

  • Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

    Robert J. Soiffer;Jennifer LeRademacher;Vincent Ho;Fangyu Kan

Frequent Co-Authors

Don M. Benson
Don M. Benson The Ohio State University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Robert J. Soiffer
Robert J. Soiffer Harvard University
Ravi Vij
Ravi Vij Washington University in St. Louis
Michael R. Grever
Michael R. Grever The Ohio State University
Jianhua Yu
Jianhua Yu City Of Hope National Medical Center
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin
John F. DiPersio
John F. DiPersio Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA often leads students beyond the traditional MD route. Many online degrees provide faster and more flexible pathways into healthcare roles. For those interested in advancing in nursing, options like the quickest dnp program can help experienced nurses earn a Doctor of Nursing Practice degree in less time.

If you need a less demanding academic load or are looking for more manageable coursework, the easiest dnp program online highlights several programs that focus on flexibility and accessibility. These are ideal for working professionals balancing education with personal commitments.

Entry-level opportunities like becoming a Licensed Practical Nurse can also be streamlined. The fast track lpn programs allow you to start working in healthcare sooner, with many options offered entirely online.

Psychiatry and mental health are growing fields, and if you want to specialize, the fastest psychiatric nurse practitioner program can help you qualify for these high-demand roles quickly and efficiently.

Best Scientists Citing Steven M. Devine

Trending Scientists

Recently Published Articles